In vivo xenograft model

CB17/severe combined immunodeficient mice were obtained from CLEA Japan, Inc and were transplanted with TMD-8 cells at 6 weeks of age. The TMD-8 cells were subcutaneously injected into the mice at a dose of 1 × 10⁷ cells per mouse with Matrigel (Corning, 356237). Tumors reached an average volume of 180 to 200 mm³ 15 days after inoculation, after which the mice were divided into 4 groups based on tumor size. Vehicle control or UBX-382 was then administered orally at doses of 3, 10, or 30 mg/kg once a day for 21 days. The mice were observed for 8 weeks following the final administration for tumor rebound. Tumors and body weight were measured thrice per week using calipers (Mitutoyo, CD-15APX), and tumor volume was calculated using the formula length × width² × 0.5. All animal experiments with mice were conducted according to guidelines approved by the Institutional Animal Care and Use Committee at Ubix Therapeutics.